Table 4.
Proportion of variance explained in the QoL parameters by each of the demographic and clinical variables for the boost groups (IORT-EBRT, IORTboost, and EBRTboost; results from univariate linear regression analyses)
| Global health status | Restrictions in daily activities | General pain | Breast symptoms | Arm symptoms | |
|---|---|---|---|---|---|
| Age |
3,1%* |
2,1% |
4,5%* |
1% |
0,0% |
| Married/partnered |
0,9% |
1,6% |
1,1% |
0,6% |
0,3% |
| Employed |
2,4% |
3,7%* |
4,8%* |
0,0% |
0,7% |
| Months since BCS |
2,6%* |
1,2% |
0,3% |
1,4% |
0,8% |
| Tumor size |
1,3% |
0,5% |
0,8% |
0,2% |
0,2% |
| Nodal involvement |
0,6% |
0,3% |
1,3% |
1,3% |
0,3% |
| ALND |
1,0% |
0,0% |
0,0% |
0,8% |
0,0% |
| Chemotherapy |
3,4%* |
3,3%* |
4,5%* |
0,3% |
0,2% |
| Endocrine therapy |
0,0% |
0,2% |
0,0% |
0,7% |
0,1% |
| Radiotherapy of supra- and infraclavicular nodes |
1,0% |
0,0% |
0,2% |
0,6% |
0,1% |
| Medical comorbidities ≥2 | 15,0%** | 11,0%** | 17,7%** | 0,0% | 4,9%* |
* p < 0,05 in the univariate analysis.
** p < 0,05 in the univariate and multivariate analyses.